


PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  March 5, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein	FILING DATE March 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/B.K./	C269	Chertkow, H., "Mild Cognitive Impairment," <i>Curr. Opin. in Neurol.</i> 15:401-407 (2002).
	C270	Clarke, A., "A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition," <i>J. Neural. Transm.</i> 110:1241-1255 (2003).
	C271	Gauthier, S., <i>et al.</i> , "Mild Cognitive Impairment," <i>The Lancet</i> 367:1262-1270 (2006).
	C272	Grundman, M., <i>et al.</i> , "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," <i>Arch. Neurol.</i> 61:59-66 (2004).
	C273	Halgren, E., <i>et al.</i> , "Human Hippocampal Formation EEG Desynchronizes During Attentiveness and Movement," <i>Electroencephalography and Clinical Neurophysiology</i> 44:778-781 (1978).
	C274	Lynch, G., <i>et al.</i> , "The Nature and Causes of Hippocampal Long-term Potentiation," <i>Progress in Brain Research</i> 83:233-250 (1990).
	C275	Mild Cognitive Impairment. Alzheimer's Society Information Sheet [online], March 2005. Retrieved from the Internet <URL: http://www.alzheimers.org.uk >.
	C276	Mild Cognitive Impairment-Alzheimer's Disease Part XVI [online], November 2006 [retrieved on 2007-01-24]. Retrieved from the Internet <URL: http://www.therubins.com >.
	C277	Meeker, J.S. and Reynolds, P.C., "Postmortem Tissue Methamphetamine Concentrations Following Selegiline Administration," <i>J. of Analytical Toxicology</i> 14:330-331 (1990).
	C278	Nickel, B., <i>et al.</i> , "Evaluation of Physical Dependence Liability of <i>l</i> -deprenyl (Selegiline) in Animals," <i>Clinical Pharmacology & Therapeutics</i> , 56(6):757-767 (1994).
	C279	Petersen, R.C., <i>et al.</i> , "Current Concepts in Mild Cognitive Impairment," <i>Arch Neurol.</i> 58:1985-1992 (2001).
	C280	Uchida, S., <i>et al.</i> , "Cortical Oscillations in Human Medial Temporal Lobe During Wakefulness and All-night Sleep," <i>Brain Research</i> 891:7-19 (2001).
	C281	Yasar, S., <i>et al.</i> , "Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(-)-Deprenyl]," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 317(1):387-394 (2006).
↓	C282	Kwon, Y. S., <i>et al.</i> , "Selegiline Potentiates the Effects of Egb 761 in Response to Ischemic Brain Injury," <i>Neurochemistry International</i> 45:157-170 (2004).

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 07/19/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 5, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-011		APPLICATION NO. 10/791,223	
	FIRST NAMED INVENTOR Mel H. Epstein		FILING DATE March 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. 3953	GROUP 1614	

/B.K./	C283	Semkova, I., <i>et al.</i> , "Selegiline Enhances NGF Synbthesis and Protects Central Nervous System Neurons from Excitotoxic and Ischemic Damage," <i>European Journal of Pharmacology</i> 315:19-30 (1996).
/B.K./	C284	Sivenius, J., <i>et al.</i> , "Selegiline Treatment Facilitates Recovery After Stroke," <i>Neurorehabilitation and Neural Repair</i> 15:183-190 (2001).

697835_1.DOC

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 07/19/2007
-------------------------------	-----------------------------------

[illegible]

C:\NrPortbl\lmanage\RLONG\730246_1.DOC